• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Erythorbic Acid (Molecular Formula:C₆H₈O₆)
Sodium Erythorbate(Molecular Formula:C₆H₇NaO₆·H₂O)
water filter
WATER FILTER FOR WATER PURIFIER
DUST BAG
Small dust filter

Perrigo Secures API Divestiture for $110M

contractpharmNovember 22, 2017

Tag: Perrigo , API

Perrigo Company has completed the divestiture of its active pharmaceutical ingredient (API) business based in Israel to SK Capital for $110 million. The company is also one of the world's largest manufacturers of over-the-counter (OTC) healthcare products and suppliers of infant formulas.

"Actions taken as part of this review process have enabled us to simplify, focus and execute on our core businesses. We continue to look at capital deployment opportunities that drive value for shareholders and further our mission of providing quality, affordable healthcare products to consumers around the globe," said Perrigo's chief executive officer, John T. 

Previous:Tiny Corbus Aims to Have Four Drugs in Mid- to Late-Stage Development by Next Year

Next:FDA approves first two-drug regimen for certain patients with HIV

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Perrigo Secures API Divestiture for $110M | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

MIRTAZAPINE

MIRTAZAPINE
TiaMax®（Tiamulin Fumarate）API/80%/45%/10%

TiaMax®（Tiamulin Fumarate）API/80%/45%/10%
Mirtazapine

Mirtazapine
Malaria Pf Antigen Rapid Test

Malaria Pf Antigen Rapid Test
salinomycin monosodium salt hydrate12%，17%，24%，40%supplier Pharmaceutical API Anti parasitic drugs V

salinomycin monosodium salt hydrate12%，17%，24%，40%supplier Pharmaceutical API Anti parasitic drugs V
Gefapixant Citrate

Gefapixant Citrate
APIXABAN

APIXABAN
Carnosic acid 60% 70% supplier API Plant extract Pharmaceutical made in china

Carnosic acid 60% 70% supplier API Plant extract Pharmaceutical made in china
Protirelin API Pharmaceutical Polypeptide supplier made in china

Protirelin API Pharmaceutical Polypeptide supplier made in china
Non-PVC Soft-bag Form-Fill-Seal Machine other api equipment

Non-PVC Soft-bag Form-Fill-Seal Machine other api equipment

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service